Share This Page
Drug Price Trends for NDC 00065-0096
✉ Email this page to a colleague
Average Pharmacy Cost for 00065-0096
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00065-0096
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00065-0096
Introduction
The drug under National Drug Code (NDC) 00065-0096 is a prescriptive pharmaceutical product within the US healthcare system. To understand its current market landscape and forecast future pricing, a comprehensive analysis encompassing therapeutic category, market demand, competitive environment, regulatory considerations, and pricing trends is essential. This report synthesizes these elements to deliver an accurate, data-driven outlook for stakeholders, investors, and healthcare providers.
Therapeutic Area and Indication
NDC 00065-0096 corresponds to Erythromycin Ophthalmic Ointment 0.5%, categorized under antibiotics. Primarily indicated for bacterial conjunctivitis and other ocular infections, erythromycin ophthalmic ointment is a staple in ophthalmic antimicrobial therapy, often designated as a first-line or adjunct treatment.
Implication: The enduring demand for erythromycin ointment stems from its established safety profile, efficacy, and low cost. The market penetration is high among ophthalmologists and pediatricians, with usage driven by the prevalence of conjunctivitis and ocular infections.
Market Size and Demand Dynamics
The global market for ophthalmic antibiotics, including erythromycin formulations, is projected to reach approximately $1.2 billion by 2025, driven predominantly by chronic infection management and prophylactic applications in surgical settings (Source: Grand View Research). Within the US, the ophthalmic antibiotic segment accounts for roughly $300 million annually, with erythromycin ointment holding a significant share due to its low cost and longstanding clinical use.
Key demand drivers include:
- Prevalence of ocular infections: Estimated 3-5% of primary care visits involve conjunctivitis, with millions of cases annually.
- Pediatric population: Higher incidence rates in children, sustaining consistent demand.
- Prophylactic use in eye surgeries: Consistent clinical practice favors stable demand.
Market challenges:
- Rising resistance patterns may influence prescription preferences.
- The emergence of newer, broad-spectrum agents can slightly diminish erythromycin's market share but generally do not replace it in initial treatment algorithms.
Competitive Landscape
The erythromycin ophthalmic ointment market faces competition from:
- Alternative antibiotics: Bacitracin, polymyxin B, and newer fluoroquinolone eye drops (e.g., Ciprofloxacin, Moxifloxacin).
- Generic manufacturers: The drug's generic status ensures high competition and price sensitivity.
- Brand-name counterpart: Exceptional price pressure on branded formulations limits price growth.
Major generic manufacturers include Allergan, Amneal, and Sandoz, among others. The presence of multiple suppliers fosters a highly competitive landscape, exerting downward pressure on prices. Although patent protections are no longer in effect, manufacturing compliance and quality standards serve as barriers to new entrants, maintaining stability in supply.
Regulatory and Pricing Environment
FDA approval categorizes erythromycin ophthalmic ointments as generics, simplifying market entry and promoting price erosion through increased competition. The drug's safety profile has long been established, with minimal regulatory hurdles for generic manufacturing.
Pricing structures:
- Retail prices trend around $3–$7 per tube (varies by supplier and pharmacy distribution).
- Insurance reimbursements and Medicare Part D or Part B coverage influence consumer out-of-pocket costs.
- State Medicaid programs often negotiate lower reimbursement rates, further impacting pricing.
Recent trends show a gradual decline in unit prices driven by:
- Market saturation of generics.
-
Increased manufacturer competition.
- Price transparency and formulary negotiations.
Price Projections
Based on current trends, the following projections are reasonable:
| Year | Predicted Price per Tube | Rationale |
|---|---|---|
| 2023 | $3.50 – $4.00 | Stable competition maintains low-to-moderate pricing. |
| 2024 | $3.25 – $3.75 | Slight downward pressure due to market saturation. |
| 2025 | $3.00 – $3.50 | Continued generic competition; marginal price erosion. |
| 2026+ | $2.75 – $3.25 | Long-term stabilization at lower margins driven by generic proliferation. |
Note: Price fluctuations are heavily influenced by supply chain factors, raw material costs, and policy changes, particularly regarding healthcare reimbursement.
Market Risks and Opportunities
Risks:
- Emergence of resistant bacterial strains may reduce prescription volume.
- Regulatory shifts favoring alternative therapies or stricter compounding standards.
- Pricing pressures from payer systems and increased emphasis on cost containment.
Opportunities:
- Potential for biosimilar or innovative delivery system entrants.
- Expansion in developing markets with increasing ophthalmic infection burdens.
- Opportunities in combination formulations, potentially commanding premium pricing.
Conclusion
The erythromycin ophthalmic ointment (NDC 00065-0096) operates within a mature, highly competitive market characterized by persistent demand and aggressive price competition. Industry fundamentals suggest a gradual decline in per-unit pricing over the next three years, barring unforeseen market disruptions. Given the drug's established position as a generic staple, investors and healthcare providers should weigh volume stability against the declining price trend when evaluating future procurement or investment strategies.
Key Takeaways
- Stable Demand: Chronic and acute ocular infections guarantee steady demand for erythromycin ointment.
- Pricing Outlook: Expect continued modest decline in unit prices due to intense generic competition.
- Market Risks: Resistance patterns and policy shifts could impact prescription volumes.
- Growth Opportunities: Market expansion into underserved regions alongside innovation in delivery methods.
- Strategic Consideration: Focus on cost-effective procurement and clinical guidelines that favor traditional antibiotics to optimize expenditure.
FAQs
-
What are the primary drivers of demand for erythromycin ophthalmic ointment?
The high prevalence of bacterial conjunctivitis, especially among children, and its role in prophylactic eye care during surgery sustain steady demand. -
How competitive is the market for NDC 00065-0096?
Extremely competitive, predominantly composed of generic manufacturers, which exerts significant downward pressure on prices. -
Are there significant regulatory hurdles affecting this drug?
No; as a generic medication with an established safety profile, erythromycin ophthalmic ointment faces minimal regulatory barriers, facilitating market entry and continuation. -
What factors could influence future price declines?
Increased generic competition, supply chain cost reductions, and payer negotiation strategies could further lower prices. -
Is there potential for price increases in the future?
Unlikely; market saturation and sustained competition favor a downward price trend, barring unforeseen shortages or regulatory changes.
References
[1] Grand View Research, “Ophthalmic Antibiotics Market Size, Share & Trends Analysis Report,” 2020.
[2] U.S. FDA. “Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book),” 2022.
[3] IQVIA. “National Prescription Data,” 2022.
[4] Statista. “Global Market for Ophthalmic Drugs,” 2021.
[5] Industry Analyst Reports. “Generic Ophthalmic Drugs Market Overview,” 2022.
More… ↓
